Clinical InvestigationPrevention and RehabilitationEfficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
Cited by (0)
Randomized controlled trial number NCT01644175.
Disclosures: Dr Kereiakes has been a consultant or on an advisory panel for HCRI; Ablative Solution, Inc; Boston Scientific; Abbott Vascular; and REVA Medical Inc. Dr Robinson is employed by a university that has received research funds from Amarin, Amgen, AstraZeneca, Daiichi-Sankyo, Esai, GlaxoSmithKline, Merck, Regeneron/Sanofi, and Zinfandel/Takeda; and is a consultant for Amgen, Pfizer, Sanofi, and Regeneron. Dr Cannon has received grants from Accumetrics, Arisaph, AstraZeneca, Boehringer-Ingelheim, Janssen; grants and personal fees from GlaxoSmithKline, Merck, and Takeda; and consulting fees from BMS, CSL Behring, Essentialis, Lipimedix, Pfizer, Regeneron, and Sanofi. Ms Lorenzato and Dr Chaudhari are employees and stockholders of Sanofi. Dr Pordy is an employee and stockholder of Regeneron Pharmaceuticals, Inc. Dr Colhoun is a consultant or on an advisory panel for Pfizer, Sanofi Aventis, Regeneron, Novartis, and Eli Lilly; has received research support from Roche, Pfizer, Eli Lilly, Boehringer Ingelheim, AstraZeneca; has participated in a lecture/speaker's bureau and received honorarium from Pfizer; and is a shareholder in Roche.
Author contributions: D. Kereiakes wrote the first draft and was involved in data collection, analysis, and interpretation. J. Robinson, C. Cannon, C. Lorenzato, R. Pordy, U. Chaudhari, and H. Colhoun were involved in revising the manuscript; and all were involved in the study design, data analysis, and interpretation. All authors provided final approval to submit the manuscript.